Assembly Biosciences (NASDAQ:ASMB) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report report published on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $50.00 target price on the biopharmaceutical company’s stock.

Assembly Biosciences Trading Up 1.3%

Shares of ASMB stock opened at $25.76 on Monday. The business’s 50-day moving average price is $19.06 and its 200-day moving average price is $14.43. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $26.24. The firm has a market capitalization of $197.58 million, a price-to-earnings ratio of -4.62 and a beta of 0.64.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.40. The firm had revenue of $9.63 million for the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%. On average, sell-side analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Several institutional investors have recently modified their holdings of the business. Palumbo Wealth Management LLC grew its stake in shares of Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 681 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 2,098 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 3,312 shares during the last quarter. Acadian Asset Management LLC increased its position in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Assembly Biosciences by 225.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 7,918 shares during the period. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.